Diagnostic Performance and Safety of Positron Emission Tomography with 18F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate- to Very-high-risk Prostate Cancer: Results from a Phase 3, Prospective, Multicentre Study (LIGHTHOUSE)Devaki Shilpa Surasi, Morand Piert, Ashutosh Tewari et al.|European Urology|2023Cited by 90
Safety and Survival Outcomes of<sup>177</sup>Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior<sup>223</sup>Ra treatment: The RALU StudyKambiz Rahbar, Oliver Sartor, Markus Essler et al.|Journal of Nuclear Medicine|2022Cited by 37
<sup>177</sup>Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer and Prior<sup>223</sup>Ra (RALU Study)Kambiz Rahbar, Oliver Sartor, Markus Essler et al.|Journal of Nuclear Medicine|2023Cited by 18